Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

18.61
+0.65003.62%
Post-market: 18.610.00000.00%16:10 EST
Volume:558.77K
Turnover:10.34M
Market Cap:1.42B
PE:73.72
High:18.81
Open:17.96
Low:17.73
Close:17.96
52wk High:25.77
52wk Low:3.50
Shares:76.24M
Float Shares:24.48M
Volume Ratio:0.47
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2524
EPS(LYR):-0.9836
ROE:9.28%
ROA:1.37%
PB:5.77
PE(LYR):-18.92

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, General Motors, Ford

Reuters
·
Jan 08

U.S. RESEARCH ROUNDUP-Alcoa, BlackRock, Evercore

Reuters
·
Jan 08

Monte Rosa Therapeutics Inc : Jefferies Raises Target Price to $31 From $22

THOMSON REUTERS
·
Jan 08

BRIEF-Monte Rosa Therapeutics Inc - Terminates Sales Agreement Prospectus - SEC Filing

Reuters
·
Jan 08

Press Release: Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Dow Jones
·
Jan 08

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's

Reuters
·
Jan 08

Crude Oil Down 2%; ISM Services PMI Surges In December

Benzinga
·
Jan 08

Monte Rosa Shares Hit Highest Since 2021, Last up 43.7% as Heart Drug Shows Promise in Early-Stage Trial

THOMSON REUTERS
·
Jan 07

U.S. Stock Movement | Positive Phase 1 Trial Data for MRT-8102 Sends Monte Rosa Therapeutics (GLUE.US) Soaring Over 42% Pre-Market

Stock News
·
Jan 07

BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods

Reuters
·
Jan 07

Monte Rosa Shares Rise 48.7% Premarket as Heart Drug Shows Promise in Early-Stage Trial

THOMSON REUTERS
·
Jan 07

Stock Track | Monte Rosa Therapeutics Soars 50.91% in Pre-market on Positive Phase 1 Trial Results for MRT-8102

Stock Track
·
Jan 07

Monte Rosa Therapeutics Showcases Pipeline Advances and Novel Protein Degrader Partnerships in New Presentation

Reuters
·
Jan 07

BUZZ-Monte Rosa rises as heart drug shows promise in early-stage trial

Reuters
·
Jan 07

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of Mrt-8102 Demonstrating Profound Crp Reductions in Elevated CVD-Risk Subjects

THOMSON REUTERS
·
Jan 07

Monte Rosa Therapeutics Inc - Favorable Safety Profile Observed for Mrt-8102

THOMSON REUTERS
·
Jan 07

Monte Rosa Therapeutics Inc - Phase 2 Ascvd Study Planned for 2026

THOMSON REUTERS
·
Jan 07

Monte Rosa Therapeutics Shares Rise Ahead of Study Results

Dow Jones
·
Jan 07

Monte Rosa Therapeutics Reports Interim Phase 1 Results for NEK7-Targeting MRT-8102

Reuters
·
Jan 07

Chief Scientific Officer Sharon Townson Reports Sale of Monte Rosa Therapeutics Common Shares

Reuters
·
Jan 06